Vertex Newswire

Vertex Newswire

Comprehensive Real-Time News Feed for Vertex.

Results 1 - 20 of 831 in Vertex

  1. Vertex Pharmaceuticals Incorporated (VRTX) Rating Reiterated by Cowen and CompanyRead the original story w/Photo

    Monday Feb 8 | AmericanBankingNews.com

    ... of large investors have modified their holdings of VRTX. Beacon Capital Management acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $0. Pillar Pacific Capital Management LLC boosted its stake ...

    Comment?

  2. Endurance Wealth Management Inc. Maintains Stake in Vertex Pharmaceuticals IncorporatedRead the original story w/Photo

    Monday Feb 8 | AmericanBankingNews.com

    Endurance Wealth Management Inc. maintained its position in shares of Vertex Pharmaceuticals Incorporated during the fourth quarter, according to its most recent filing with the SEC. The firm owned 6,100 shares of the pharmaceutical company's stock at the end of the fourth quarter.

    Comment?

  3. Vertex Pharmaceuticals Incorporated (VRTX) Reaches New 1-Year Low on Insider SellingRead the original story w/Photo

    Monday Feb 8 | Daily Political

    Vertex Pharmaceuticals Incorporated hit a new 52-week low on Monday following insider selling activity, Market Beat reports. The stock traded as low as $80.60 and last traded at $80.63, with a volume of 2,126,106 shares traded.

    Comment?

  4. Vertex Pharmaceuticals Has Great Upside PotentialRead the original story w/Photo

    Monday Feb 8 | The US Market Blog

    ... stocks listed, only three had positive forward PE ratios: Enzymotec (NASDAQ: ENZY ), Medivation (NASDAQ: MDVN ), and Vertex Pharmaceuticals (NASDAQ: VRTX ). Out of those three, Vertex had the cheapest forward PE (15.49) and the highest EPS growth ...

    Comment?

  5. Vertex Pharmaceuticals Incorporated (VRTX) Stock Rating Reaffirmed by Maxim GroupRead the original story w/Photo

    Monday Feb 8 | Daily Political

    ... have recently modified their holdings of the company. Beacon Capital Management purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $0. MetLife Securities Inc increased its stake in shares of ...

    Comment?

  6. BioAxone BioSciences Inc. Announces NIH/SBIR Fast Track Grant to...Read the original story w/Photo

    Monday Feb 8 | Market Wire

    ... signaling pathways. The company's lead drug for spinal cord injuries, VX-210 (formerly Cethrin), was licensed to Vertex Pharmaceuticals and is expected to enter a Phase IIb/III clinical study in the first half of 2016. BioAxone's research programs ...

    Comment?

  7. Paul M. Silva Sells 5,062 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockRead the original story w/Photo

    Monday Feb 8 | Daily Political

    Vertex Pharmaceuticals Incorporated SVP Paul M. Silva sold 5,062 shares of the firm's stock in a transaction on Wednesday, February 3rd. The stock was sold at an average price of $90.82, for a total value of $459,730.84.

    Comment?

  8. Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Down 6.7% After Insider SellingRead the original story w/Photo

    Sunday Feb 7 | Daily Political

    Vertex Pharmaceuticals Incorporated 's share price traded down 6.7% on Friday following insider selling activity, MarketBeat reports. The company traded as low as $85.18 and last traded at $85.61, with a volume of 2,753,428 shares traded.

    Comment?

  9. FDA Spurns Vertex Application for Expanded Use of KalydecoRead the original story

    Thursday Feb 4 | BioSpace

    Vertex Pharmaceuticals Incorporated today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental New Drug Application for the use of KALYDECOA in people with cystic fibrosis ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator gene. The FDA determined that it cannot approve the application in its present form.

    Comment?

  10. Joshua S. Boger Sells 5,130 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockRead the original story w/Photo

    Friday Feb 5 | Daily Political

    Vertex Pharmaceuticals Incorporated Director Joshua S. Boger sold 5,130 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 3rd. The shares were sold at an average price of $90.81, for a total transaction of $465,855.30.

    Comment?

  11. Vertex Pharmaceuticals Incorporated (VRTX) Trading Down 6.7% After Insider SellingRead the original story w/Photo

    Friday Feb 5 | AmericanBankingNews.com

    Vertex Pharmaceuticals Incorporated 's share price traded down 6.7% on Friday after an insider sold shares in the company, MarketBeat.Com reports. The company traded as low as $85.18 and last traded at $85.61, with a volume of 2,753,428 shares trading hands.

    Comment?

  12. Here's Why Shares Of Vertex Pharmaceuticals TumbledRead the original story

    Friday Feb 5 | Benzinga

    Shares of Vertex Pharmaceuticals Incorporated tumbled by more than 6 percent on Friday after the company confirmed it has received a letter from the U.S. Food and Drug Administration for use of Kalydeco in people with cystic fibrosis. Vertex Pharmaceuticals said that it received a Complete Response Letter from the U.S. FDA for its supplemental New Drug Application for the use of Kalydeco.

    Comment?

  13. Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeffrey M. Leiden Sells 9,834 SharesRead the original story w/Photo

    Friday Feb 5 | Daily Political

    Vertex Pharmaceuticals Incorporated CEO Jeffrey M. Leiden sold 9,834 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 3rd. The shares were sold at an average price of $90.82, for a total transaction of $893,123.88.

    Comment?

  14. Vertex Receives Complete Response Letter from U.S. FDA for Use of...Read the original story

    Friday Feb 5 | Freshnews

    Vertex Pharmaceuticals Incorporated today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental New Drug Application for the use of KALYDECO in people with cystic fibrosis ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator gene. The FDA determined that it cannot approve the application in its present form.

    Comment?

  15. Ian F. Smith Sells 12,084 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockRead the original story w/Photo

    Thursday Feb 4 | AmericanBankingNews.com

    Vertex Pharmaceuticals Incorporated CFO Ian F. Smith sold 12,084 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, February 3rd. The shares were sold at an average price of $90.84, for a total transaction of $1,097,710.56.

    Comment?

  16. Stuart A. Arbuckle Sells 6,042 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockRead the original story w/Photo

    Thursday Feb 4 | AmericanBankingNews.com

    Vertex Pharmaceuticals Incorporated EVP Stuart A. Arbuckle sold 6,042 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 3rd. The stock was sold at an average price of $90.82, for a total value of $548,734.44.

    Comment?

  17. Leerink Swann Initiates Coverage on Vertex Pharmaceuticals IncorporatedRead the original story w/Photo

    Thursday Feb 4 | AmericanBankingNews.com

    ... of large investors have recently bought and sold shares of VRTX. American Century Companies Inc. raised its stake in Vertex Pharmaceuticals by 24.8% in the fourth quarter. American Century Companies Inc. now owns 1,510,545 shares of the ...

    Comment?

  18. Vertex Pharmaceuticals Incorporated (VRTX) Price Target Lowered to $140.00 at ArgusRead the original story w/Photo

    Thursday Feb 4 | AmericanBankingNews.com

    ... stock. Argus' target price would indicate a potential upside of 49.13% from the stock's previous close. In other Vertex Pharmaceuticals news, Director Yuchun Lee sold 1,125 shares of the company's stock in a transaction dated Monday, January 4th. ...

    Comment?

  19. Analysts' Recent Ratings Changes for Vertex PharmaceuticalsRead the original story w/Photo

    Thursday Feb 4 | AmericanBankingNews.com

    They now have a $155.00 price target on the stock. 2/1/2016 - Vertex Pharmaceuticals was upgraded by analysts at Jefferies Group from a "hold" rating to a "buy" rating.

    Comment?

  20. Regeneron Stock Rocks, but Vertex, Medivation & Jazz Pharma RollRead the original story

    Tuesday Feb 2 | BioSpace

    ... 's shares are fetching a premium price." As a result, he suggest there are some better deals out there, citing Vertex Pharmaceuticals ( VRTX ), Medivation ( MDVN ), and Jazz Pharmaceuticals PLC ( JAZZ ). Vertex Pharmaceuticals ( VRTX ) Based in ...

    Comment?